Moreover, immunohistochemical classification into either a luminal A, HER2-expressing, basal-like, or triple-negative tumors was found to be associated with a patient's survival, and tumor subtypes were shown to respond differently to adjuvant therapy, with many basal-like and HER2-positive tumors being particularly sensitive to anthracycline-based combination therapy [12],[13]. The gene discussed is ERBB2; the disease is neoplasm.